## Laurus Labs Limited (LAURUSLABS) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Laurus Labs Limited is a pharmaceutical company listed on the NSE (National Stock Exchange of India) on December 19, 2016.  It operates within the Pharmaceuticals & Biotechnology industry.  While the provided data doesn't specify its exact market positioning within the sector, its presence on the NSE and inclusion in various indices (NIFTY 500, NIFTY PHARMA, etc.) suggests a significant, albeit possibly mid-cap, role.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                                 |
|-----------------------------|-----------------|-------------------------------------------------------------------------|
| Current Price               | 558.5           | Closed at 559.2, slightly down from the pre-open price.                 |
| Percentage Change (PChange) | -2.45%          | Significant negative daily change.                                      |
| Pre-Open Activity          | 572.8 (Open)    |  Opened higher than the previous close, indicating initial buying interest. |
| Week High                   | 593             | Indicates recent upward price momentum.                               |
| Week Low                    | 360.85          | Shows significant price volatility over the week.                       |
| VWAP                        | 565.18          | Volume Weighted Average Price suggests a slightly higher average trading price. |
| Sector PE                   | 236.69          | High Price-to-Earnings ratio for the sector, indicating potential overvaluation. |
| Symbol PE                   | 236.69          | High Price-to-Earnings ratio for the stock, indicating potential overvaluation. |
| Delivery Percentage         | 53.71%          | Moderately high delivery percentage, suggesting some genuine investment interest. |
| Market Depth                | Low              | The provided market depth data (total buy/sell quantities at various price points) is zero, indicating insufficient data for a proper analysis.  Further investigation is needed. |


**3. Financial Performance:**

The provided financial data shows a mixed performance over the last five quarters.  While Q1 2024 showed strong profit after tax (PAT) and EPS, subsequent quarters have seen a decline.  This needs further investigation to determine if this is a temporary trend or a longer-term issue.

| Quarter      | Revenue     | Expenditure | Profit After Tax | EPS     |
|--------------|-------------|-------------|-------------------|---------|
| Q1 2024      | 143,861     | 127,430     | 12,132            | 2.25    |
| Q2 2024      | 112,623     | 108,743     | 2,878             | 0.53    |
| Q3 2024      | 119,674     | 113,865     | 4,244             | 0.79    |
| Q4 2023      | 114,291     | 108,621     | 4,264             | 0.79    |
| Q3 2023      | 116,393     | 110,072     | 4,667             | 0.87    |


**Key Financial Ratios:**  Further analysis requires more detailed financial statements to calculate key ratios like Return on Equity (ROE), Debt-to-Equity ratio, and others.  The current data only provides EPS.

**4. Corporate Actions and Announcements:**

Recent corporate actions include interim dividends (Rs 0.40 per share on Nov 6, 2024, and previous quarters).  A face value split occurred in September 2020.  Numerous announcements regarding analyst meetings and press releases suggest active investor relations.  The recent dividend announcement is positive.

**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group | Public | Shares held by Employee Trusts | Total |
|--------------|---------------------------|--------|-------------------------------|-------|
| 30-Sep-2023  | 27.20%                     | 72.80% | 0.00%                         | 100.00%|
| 31-Dec-2023  | 27.19%                     | 72.81% | 0.00%                         | 100.00%|
| 31-Mar-2024  | 27.19%                     | 72.81% | 0.00%                         | 100.00%|
| 30-Jun-2024  | 27.18%                     | 72.82% | 0.00%                         | 100.00%|
| 30-Sep-2024  | 27.18%                     | 72.82% | 0.00%                         | 100.00%|

Promoter shareholding has remained relatively stable over the past year, indicating confidence in the company's prospects.

**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the week's high and low prices.  The CM Annual Volatility of 37.25% further confirms this.  The risk-reward profile is currently skewed towards risk due to the recent price decline and high volatility.  Further analysis using historical data would provide a more comprehensive risk assessment.

**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* Presence in a growing pharmaceutical sector.
* Relatively stable promoter holding.

**8. Disadvantages and Risks:**

* High volatility.
* Declining financial performance in recent quarters (needs further investigation).
* High PE ratio compared to the sector, suggesting potential overvaluation.
* Insufficient market depth data.

**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold/Don't Buy.** The recent price drop and high volatility make a short-term buy risky.  The lack of market depth data further increases uncertainty.  Holding if already invested is advisable, but new investment is not recommended.

* **Medium-term (3 to 12 months): Hold.**  The medium-term outlook depends on the company's ability to reverse the recent decline in financial performance.  Further investigation into the reasons for this decline is crucial.  The consistent dividend payouts offer some support.

* **Long-term (1 year and beyond): Hold/Don't Buy.**  Long-term investment requires a thorough understanding of the company's long-term growth strategy and its ability to compete in the pharmaceutical sector.  The high PE ratio needs to be considered.  Further research is needed before recommending a long-term buy.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.0**

* Financial Health: 5/10 (Declining profits in recent quarters are concerning.)
* Market Performance: 4/10 (High volatility and recent price drop.)
* Volatility and Risk: 3/10 (High volatility is a significant risk.)
* Corporate Actions & Governance: 8/10 (Consistent dividends and active investor relations are positive.)
* Shareholding Patterns: 7/10 (Stable promoter holding is positive.)

**Analysis Score (out of 10): 7.0**

* Completeness and Data Utilization: 8/10 (Most data points were used, but some limitations exist.)
* Accuracy and Clarity: 7/10 (Analysis is clear, but some conclusions are tentative due to data limitations.)
* Professional Formatting: 8/10 (Report is well-structured and easy to read.)


**11. Professional Recommendation Summary:**

Based on the available data, Laurus Labs Limited presents a mixed investment picture.  While the company has a history of dividend payouts and stable promoter holdings, recent financial performance has declined, and the stock exhibits high volatility.  A "Hold" recommendation is given for the medium and long term, pending further investigation into the reasons for the recent financial downturn and a more thorough analysis of the company's long-term prospects.  A "Hold/Don't Buy" is recommended for the short term due to high volatility and insufficient market depth data.  Further research is strongly recommended before making any investment decisions.
